Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Femasys Inc. SEC filings document the company’s women’s health medical-device business, Nasdaq-listed common stock, operating results, and product-related corporate updates. Recent 8-K filings furnish quarterly and annual financial results and disclose material events tied to executive appointments, employment agreements, financing instruments, and listing compliance matters.
Proxy materials cover annual and special stockholder meetings, board elections and governance matters, reverse stock split authorization, and share-issuance approvals linked to capital-structure provisions. Other filings describe senior secured convertible notes, warrant amendments, Nasdaq minimum bid price compliance, and the company’s emerging growth company reporting status.
Femasys Inc. (Nasdaq: FEMY) filed a Form 8-K to disclose a material event under Item 8.01 (Other Events).
- On July 1, 2025, the Company issued a press release (Exhibit 99.1) announcing that it has obtained regulatory approvals in Australia and New Zealand for two products:
- FemaSeed for first-line infertility treatment
- FemVue diagnostic system
- No financial results, transaction details, or forward-looking guidance were included in the filing.
- The disclosure is limited to the announcement; the full press release is incorporated by reference but not reproduced in the 8-K.
The Company indicates it remains an emerging growth company.
Femasys (NASDAQ: FEMY) held its Annual Meeting of Stockholders on June 25, 2025, with 59.41% of eligible shares represented. Three key proposals were voted on:
- Director Elections: Two Class I directors were elected for three-year terms through 2028: - Alistair Milnes (4.88M votes for, 941K against) - Edward Uzialko (4.95M votes for, 876K against)
- Equity Incentive Plan Amendment: Stockholders approved increasing authorized shares under the 2021 Plan by 3 million shares (4.26M votes for, 1.58M against)
- Auditor Appointment: KPMG LLP was ratified as independent auditor for FY2025 with overwhelming support (16.10M votes for, 80K against)
The company, listed as an emerging growth company, has elected not to use extended transition periods for new accounting standards compliance.
Femasys Inc. (NASDAQ:FEMY) filed an 8-K announcing a historic milestone with the European approval of FemBloc, their first non-surgical permanent birth control solution. This marks a significant regulatory achievement for the emerging growth company, potentially opening up the European market for their innovative medical device. The announcement was made via press release on June 25, 2025, representing a major development in the company's women's healthcare portfolio.